Drugs – Generic

(MYL) Favorable Verdict for Mylan

Mylan Inc. (MYL) recently announced that the Court of Appeals for the Federal Circuit has issued a favorable verdict for the company in a patent infringement case. The court overturned the decision of the District Court invalidating...

25Aug2013 | | Comments Off on (MYL) Favorable Verdict for Mylan | Continued

(ACT) Actavis to Buy Warner Chilcott

Actavis, Inc. (ACT) recently announced its intention to acquire Warner Chilcott plc (WCRX) in a stock-for-stock transaction worth about $8.5 billion. This includes...

19Aug2013 | | Comments Off on (ACT) Actavis to Buy Warner Chilcott | Continued

(MYL) Mylan Continues to Launch New Generic Versions of Drugs

Mylan Inc. (MYL) recently announced the launch of its generic version of AbbVie Inc.‘s (ABBV) cholesterol management drug, TriCor (fenofibrate, 48 mg and 145...

25Jul2013 | | Comments Off on (MYL) Mylan Continues to Launch New Generic Versions of Drugs | Continued

(ACT) Actavis Beats on Earnings – Raises View

Actavis, Inc.’s (ACT) first quarter 2013 earnings of $1.99 per share beat the Zacks Consensus Estimate of $1.87 and increased 21% from the year-ago earnings.

Revenues for the reported quarter came in at approximately $1,895.5...

14May2013 | | Comments Off on (ACT) Actavis Beats on Earnings – Raises View | Continued

(MYL) Still Neutral on Mylan

We are maintaining our Neutral recommendation on Mylan Inc. (MYL) with a target price of $30.00.

Why the Reiteration?

Mylan performed well in the fourth quarter of 2012. Mylan’s fourth quarter 2012...

26Apr2013 | | Comments Off on (MYL) Still Neutral on Mylan | Continued

(WPI) Watson Pharmaceuticals Files Velcade Abbreviated New Drug Application

Watson Pharmaceuticals, Inc. (WPI) recently announced that it is seeking FDA approval for its generic version of Millennium Pharma’s Velcade (bortezomib). Millennium Pharma is a wholly-owned subsidiary of Takeda Pharma...

5Jan2013 | | Comments Off on (WPI) Watson Pharmaceuticals Files Velcade Abbreviated New Drug Application | Continued

(MYL) Another Generic Launch at Mylan

Mylan Inc. (MYL) recently announced that it has launched its generic version of Teva’s (TEVA) Nordette 28 Tablets (levonorgestrel and ethinyl estradiol – 0.15...

1Jan2013 | | Comments Off on (MYL) Another Generic Launch at Mylan | Continued

(WPI) An End to Drug Patent Woes?

The US Supreme Court will soon hear a case which will determine whether “pay-for-delay” agreements between drug manufacturers violate anti-trust legislations. These “reverse payment” agreements enable patent holders to pay generic drug manufacturers to delay the launch of generic versions...

16Dec2012 | | Comments Off on (WPI) An End to Drug Patent Woes? | Continued

(WPI) Watson Pharmaceuticals Earns FDA Approval for Generic Sanctura XR

Watson Pharmaceuticals, Inc. (WPI) recently announced that it has gained US Food and Drug Administration (FDA) approval for its generic version of Allergan’s (AGN)...

15Nov2012 | | Comments Off on (WPI) Watson Pharmaceuticals Earns FDA Approval for Generic Sanctura XR | Continued

(WPI) Watson Pharmaceuticals Earns EC Nod for Actavis Deal

Watson Pharmaceuticals, Inc. (WPI) recently received the green signal from the European Commission (EC) for its proposed acquisition of privately-held generic pharma company Actavis. The EC said that although the acquisition will lead...

23Oct2012 | | Comments Off on (WPI) Watson Pharmaceuticals Earns EC Nod for Actavis Deal | Continued

(MYL) Mylan in Neutral Lane

We are maintaining our Neutral recommendation on Mylan Inc. (MYL) with a target price of $26.00. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Mylan performed well in the second quarter of 2012, beating the...

23Oct2012 | | Comments Off on (MYL) Mylan in Neutral Lane | Continued

(WPI) Watson Pharmaceuticals A Step Closer to Actavis

Watson Pharmaceuticals, Inc. (WPI) recently received a favorable vote from the Federal Trade Commission (FTC) for its proposed acquisition of the Actavis group of companies. However, Watson Pharma will be required to sell certain products.

These...

20Oct2012 | | Comments Off on (WPI) Watson Pharmaceuticals A Step Closer to Actavis | Continued

(MYL) More Generic Launches at Mylan

Mylan Pharmaceuticals Inc., a subsidiary of Mylan Inc. (MYL), recently announced that it has launched its generic version of Sanofi’s (SNY) Avapro (irbesartan)...

9Oct2012 | | Comments Off on (MYL) More Generic Launches at Mylan | Continued

(WPI) Watson Pharmaceuticals Has Generic Xopenex Launch

Watson Pharmaceuticals Inc. (WPI) recently announced the launch of an authorized generic version of Sunovion Pharmaceuticals Inc.’s Xopenex (levalbuterol HCl) inhalation solution. Xopenex is used for the treatment or prevention of...

22Aug2012 | | Comments Off on (WPI) Watson Pharmaceuticals Has Generic Xopenex Launch | Continued

(PRX) Par Pharmaceuticals Companies to be Aquired by TPG

Yet another acquisition agreement was recently announced in the pharma sector. US based specialty pharmaceutical company Par Pharmaceuticals Companies Inc. (PRX) entered into an agreement with an affiliate of leading global private...

21Aug2012 | | Comments Off on (PRX) Par Pharmaceuticals Companies to be Aquired by TPG | Continued

(MYL) Mylan Incorporated – Bull of the Day

Mylan, Inc. (MYL) is one of the leading players in the US generics market. The company holds immense potential as many blockbuster drugs have begun to go off-patent and many more will lose patent exclusivity in the next few years.

Moreover,...

30Jan2012 | | 0 comments | Continued

(MYL) Mylan Earns FDA Approval

Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol...

5Dec2011 | | 0 comments | Continued

(MYL) Mylan Approved for Zinecard Generic

Mylan, Inc.’s (MYL) generic business was boosted further with the approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pharmacia & Upjohn’s Zinecard injection. Zinecard injection, which is...

1Dec2011 | | 0 comments | Continued

(MYL) Mylan Settles with Novartis

Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot....

28Nov2011 | | 0 comments | Continued

(WPI) Watson Pharmaceuticals – Bull of the Day

Watson Pharmaceuticals, Inc. (WPI) posted second-quarter 2011 earnings of $1.01 per share, beating the Zacks Consensus Estimate by a penny and the year-ago earnings by $0.18 per share. Earnings were boosted by strong revenues, which...

31Oct2011 | | 0 comments | Continued

(MYL) Mylan Settles with Roche for Xeloda

Mylan Inc. (MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s cancer drug Xeloda....

23Sep2011 | | 0 comments | Continued

(WPI) Watson Pharmaceuticals Analyst Maintains Outperform on Shares

We continue to have an Outperform recommendation on Watson Pharmaceuticals, Inc. (WPI), with a target price of $79.00, following the release of second quarter 2011 results.

Watson Pharma’s second quarter earnings of $1.01...

26Aug2011 | | 0 comments | Continued

(MYL) Mylan Analyst Reaffirms Shares at Neutral

We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results.

Mylan’s second quarter 2011 earnings (excluding special items)...

25Aug2011 | | 0 comments | Continued

(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle

Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA)...

18Aug2011 | | 0 comments | Continued

(MYL) Mylan Beats Second Quarter Earnings on All Fronts

Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven...

27Jul2011 | | 0 comments | Continued

(WPI) Watson Pharmaceuticals – Bull of the Day

Based on its first quarter performance and increased guidance, we are upgrading Watson Pharmaceuticals (WPI) to Outperform. The company posted first-quarter 2011 earnings of $0.89 per share, beating the Zacks Consensus Estimate by...

14Jul2011 | | 0 comments | Continued

(MYL) Mylan Gets HIV Rights from Gilead

Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc....

14Jul2011 | | 0 comments | Continued

(WPI) Watson Pharmaceuticals Entangled in Legal Dispute

The legal tussle between Watson Pharmaceuticals Inc. (WPI) and Shire plc (SHPGY) intensified, with the latter filing a patent infringement case against Watson Pharma...

8Jul2011 | | 0 comments | Continued

(PRX) Par Pharmaceutical Restructures Branded Business

Par Pharmaceutical Companies, Inc. (PRX) is in for a strategic assessment as it announced restructuring plans for its branded drugs segment, Strativa Pharmaceuticals. The company will reduce its workforce by about 100 people as a result...

5Jul2011 | | 0 comments | Continued

(WPI) Watson Pharmaceuticals and Columbia Laboratories Drug’s NDA Accepted

Watson Pharmaceuticals Inc. (WPI) along with Columbia Laboratories Inc. (CBRX) recently announced that the latter’s New Drug Application (NDA) for Prochieve (progesterone...

29Jun2011 | | 0 comments | Continued